The MarketWatch News Department was not involved in the creation of this content.-- VYVGART(R) SC is first and only neonatal Fc receptor blocker approved to treat CIDP -- Authoriz ...

CONSHOHOCKEN, Pa., May 8, 2025 /PRNewswire/ -- The GBS | CIDP Foundation International is commemorating Guillain-Barré Syndrome and Chronic Inflammatory Demyelinating Polyneuropathy Awareness Month ...

(BPT) – “At first I was kind of like, what is that? What is CIDP? I’ve never heard of that. But then, the relief set in more than confusion … because at least there was a name to what I had.” ...

The purpose of the Benson Fellowship is to encourage professional training in the peripheral inflammatory neuropathy area for medical doctors, and to encourage philanthropic support to help address ...

A 12-year-old held an art festival Saturday to benefit a rare disorder that his mother has. Jace Ricciuti held the event downtown for chronic inflammatory demyelinating polyneuropathy, also known as ...

Want to take a walk or roll to help a global charity find new strides in getting its message out? Then join the “Walk & Roll” for GBS-CIDP, at 10 a.m. Saturday for 1 mile across Conway’s Riverfront ...

The FDA on March 16 approved CSL Behring’s drug Hizentra to treat chronic inflammatory demyelinating polyneuropathy. Hizentra is the first subcutaneous immunoglobulin approved to treat CIDP, a rare ...

KING OF PRUSSIA, Pa., June 8, 2021 /PRNewswire/ — Global biotherapeutics leader CSL Behring today announced that the Centers for Medicare & Medicaid Services (CMS) has approved Hizentra for coverage ...

KING OF PRUSSIA, Pa., Dec. 9, 2019 /PRNewswire/ -- Global biotherapeutics leader CSL Behring announced today that Hizentra received orphan-drug exclusivity from the U.S. Food and Drug Administration ...

CONSHOHOCKEN, Pa., May 8, 2025 /PRNewswire/ -- The GBS | CIDP Foundation International is commemorating Guillain-Barré Syndrome and Chronic Inflammatory Demyelinating Polyneuropathy Awareness Month ...